GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » E10

Acorda Therapeutics (Acorda Therapeutics) E10 : $-227.84 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Acorda Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-175.320. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-227.84 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was -40.90% per year. During the past 5 years, the average E10 Growth Rate was -55.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Acorda Therapeutics was 69.80% per year. The lowest was -73.90% per year. And the median was -38.90% per year.

As of today (2024-05-15), Acorda Therapeutics's current stock price is $0.38. Acorda Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-227.84. Acorda Therapeutics's Shiller PE Ratio of today is .


Acorda Therapeutics E10 Historical Data

The historical data trend for Acorda Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics E10 Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.49 -81.47 -118.81 -194.76 -227.84

Acorda Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -194.76 -198.98 -203.31 -208.65 -227.84

Competitive Comparison of Acorda Therapeutics's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Shiller PE Ratio falls into.



Acorda Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Acorda Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-175.32/129.4194*129.4194
=-175.320

Current CPI (Dec. 2023) = 129.4194.

Acorda Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 2.400 99.695 3.116
201406 13.200 100.560 16.988
201409 33.600 100.428 43.300
201412 1.200 99.070 1.568
201503 -8.400 99.621 -10.913
201506 2.400 100.684 3.085
201509 10.800 100.392 13.923
201512 25.200 99.792 32.682
201603 -1.200 100.470 -1.546
201606 -48.000 101.688 -61.090
201609 -33.600 101.861 -42.690
201612 -8.400 101.863 -10.672
201703 -49.200 102.862 -61.903
201706 -21.600 103.349 -27.049
201709 -66.000 104.136 -82.025
201712 -443.999 104.011 -552.461
201803 -21.600 105.290 -26.550
201806 117.600 106.317 143.154
201809 -34.800 106.507 -42.286
201812 24.000 105.998 29.303
201903 -120.000 107.251 -144.804
201906 -69.600 108.070 -83.350
201909 -665.999 108.329 -795.658
201912 165.600 108.420 197.674
202003 -16.200 108.902 -19.252
202006 -43.800 108.767 -52.116
202009 6.400 109.815 7.543
202012 -196.400 109.897 -231.289
202103 -70.600 111.754 -81.760
202106 -45.800 114.631 -51.708
202109 -48.600 115.734 -54.347
202112 -34.600 117.630 -38.068
202203 -37.000 121.301 -39.476
202206 -54.010 125.017 -55.912
202209 -11.170 125.227 -11.544
202212 11.400 125.222 11.782
202303 -13.800 127.348 -14.024
202306 -7.550 128.729 -7.591
202309 -7.160 129.860 -7.136
202312 -175.320 129.419 -175.320

Add all the adjusted EPS together and divide 10 will get our e10.


Acorda Therapeutics  (OTCPK:ACORQ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Acorda Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (Acorda Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Executives
Thomas M. Burns director 2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen officer: CEO and President C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser officer: Chief Financial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff officer: General Counsel 11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem officer: Chief Commercial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales officer: Interim PAO & PFO 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman officer: Exec V Pres, Gen Cnsl & Sec C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: Exec. VP-Commercial Dvlpmnt C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence officer: Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank officer: Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc. 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123

Acorda Therapeutics (Acorda Therapeutics) Headlines

From GuruFocus

Q2 2022 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q4 2020 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q1 2019 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q4 2019 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q1 2021 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q3 2023 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Acorda Therapeutics Inc CEO Video Presentation Transcript

By GuruFocus Research 02-06-2024

Acorda Therapeutics Inc Q&A Call Transcript

By GuruFocus Research 02-06-2024